SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease

Recruiting now · Phase 2

Conditions studied: Lupus Nephritis, Chronic Kidney Diseases

In brief

Lupus nephritis (LN) is a common manifestation in patients with systemic lupus erythematosus (SLE), and is an important cause of acute kidney injury and chronic kidney disease (CKD). Although the standard-of-care treatments for active severe LN are effective, a substantial proportion of LN patients still develop CKD and eventually end-stage kidney disease (ESKD). Cardiovascular complications are common and is a leading cause of death in SLE and LN patients. It is well recognized that LN patients had multiple risk factors for cardiovascular complications such as diabetes mellitus (DM), dyslipidaemia and vascular inflammation. Sodium-glucose co-transporter 2 (SGLT2) inhibitor are initially developed as an oral anti-diabetic agent and has shown to be effective in glycaemic control, has benefits in lipid metabolism, cardiovascular and renal outcomes, and also well tolerated by patients. Various trials have also demonstrated the benefits of SGLT2 inhibitor in the reduction of CKD, ESKD, and renal or cardiovascular death. However, the effect of SGLT2 inhibitor in LN remains unclear. The purpose of this study is to investigate the effect of SGLT2 on renal outcomes in LN patients with CKD, as well as the side effects, metabolic profiles, immunological functions and disease stability.

Key facts

Study ID

NCT06155604

Run by

The University of Hong Kong

People needed

150

Starts

2023-01-04

Expected to finish

2026-12-31

Last updated by the study team

2024-12-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with biopsy-proven Class III or IV or V LN according to the ISN/RPS 2003 classification
• Patients with CKD (eGFR 15-60mL/min)
• Patients in quiescent disease (defined as SLEDAI score <4 with no points in the renal domain)
• Patients on a stable dose of prednisolone (PRED 5-7.5 mg/D) alone or in combination with MMF (<=1.5 g/D) or AZA (<=150 mg/D) in the past 3 months

You may not qualify if…

• Patients with biopsy-proven glomerulonephritis other than LN or hereditary kidney diseases
• Patients with type 1 diabetes mellitus (DM)
• Patients with stage 5 CKD or ESKD on renal replacement therapy
• Patients with frequent urinary tract infections
• Patients with history of ketoacidosis

Where it is running

• Queen Mary Hospital — Hong Kong, Hong Kong (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.